Harvia Plc: Managers' transactions - David Ahonen

HARVIA PLC STOCK EXCHANGE RELEASE 3 MARCH 2025 AT 1.00 P.M. EET

Harvia Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: David Ahonen
Position: Other senior manager
 Issuer: Harvia Oyj
LEI: 7437002ULTBOWQQOXL69
Notification type: INITIAL NOTIFICATION
Reference number: 98432/4/10

____________________________________________
Transaction date: 2025-02-27
Outside a trading venue
Instrument type: SHARE
ISIN: FI4000306873
Nature of transaction: GIFT,DONATION OR INHERITANCE (MADE) 

Transaction details
(1): Volume: 105 Unit price: 0 N/A 
(2): Volume: 105 Unit price: 0 N/A 
(3): Volume: 105 Unit price: 0 N/A 
(4): Volume: 105 Unit price: 0 N/A 

Aggregated transactions (4): 
Volume: 420 Volume weighted average price: 0 N/A

Additional information:

Ari Vesterinen, CFO
tel. +358 40 5050 440
[email protected]

Harvia is one of the leading companies operating in the sauna market globally, as measured by revenue. Harvia’s brands and product portfolio are well known in the market, and the company’s comprehensive product portfolio strives to meet the needs of the international sauna market of both private and professional customers.

Harvia’s revenue totaled EUR 175.2 million in 2024. Harvia Group employs approximately 700 professionals in Finland, United States, Germany, Romania, China and Hong Kong, Austria, Italy, Estonia, and Sweden. The company is headquartered in Muurame, Finland, adjacent to its largest sauna and sauna component manufacturing facility.

Read more: https://harviagroup.com

You May Also Be Interested In

• BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
• Cryptocurrency News: $431M in Bets Wiped Out in a Day as Pepeto Buyers Chase Gains Like Ethereum’s First Holders
• Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026